NEO חוב כולל להון NeoGenomics

The debt-to-equity dynamics demonstrate the financial stability of NeoGenomics, Inc. (NEO), with the 0.54 value describing the current leverage level. The business is shielded from crises, as cancer diagnostics remain in demand regardless of economic conditions. The integration of molecular tests into clinics creates barriers to switching to competitors. The environmental strategy relies on the safe disposal of biohazardous waste and the digitalization of reporting.

The ratio is calculated as total debt relative to the organization's equity. This metric determines the degree of financial leverage and the company's dependence on external creditors. For NeoGenomics, Inc. (NEO), borrowings may serve as a tool for scaling its laboratory network and implementing costly NGS tests. An increase in the debt load may indicate aggressive expansion within the personalized medicine sector. By analyzing changes in the business's leverage ratio, an investor assesses the issuer's resilience to market shocks.